Table 2 Details of the endovascular treatment and clinical outcomes
From: Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study
|  | Non-tirofiban group (n = 59) | Tirofiban group (n = 59) | P value |
|---|---|---|---|
Onset-to-puncture time | 275 (210–482) | 395 (274–580) | 0.036 |
Puncture-to-final angiography time | 81 (60–101) | 65 (42–108) | 0.064 |
Onset-to-reperfusion time | 380 (298–646) | 467 (345–675) | 0.066 |
First-line endovascular treatment | Â | Â | 0.096 |
 Aspiration thrombectomy | 29 (49.2%) | 33 (55.9%) |  |
 Stent retriever | 23 (39.0%) | 25 (42.4%) |  |
 Local fibrinolytics | 1 (1.7%) | 1 (1.7%) |  |
 Angioplasty | 6 (10.2%) | 0 |  |
Immediate reocclusion after first endovascular method | 10 (17.9%) | 24 (41.4%) | 0.006 |
Degree of residual stenosis prior to rescue treatment (%) | 80 (71–86) | 83 (79–90) | 0.056 |
Rescue treatments | |||
 Local tirofiban infusion only | 0 | 48 (81.4%) | < 0.001 |
 Stent retriever to aspiration | 1 (1.7%) | 0 | > 0.999a |
 Aspiration to stent retriever | 8 (13.6%) | 3 (5.1%) | 0.113 |
 Intracranial balloon angioplasty | 9 (15.3%) | 2 (3.4%) | 0.027 |
 Intracranial stenting | 12 (20.3%) | 6 (10.2%) | 0.124 |
Final AOL 2–3 | 41 (69.5%) | 41 (69.5%) | > 0.999 |
Final mTICI 2b–3 | 25 (42.4%) | 51 (86.4%) | 0.016 |
Postprocedural reocclusion | 12 (37.5%, n = 32) | 2 (4.4%, n = 45) | < 0.001 |
Intracerebral hemorrhage | Â | Â | 0.311 |
 HT type 1 | 4 (6.8%) | 2 (3.4%) |  |
 HT type 2 | 6 (10.2%) | 3 (5.1%) |  |
 PH type 1 | 3 (5.1%) | 1 (1.7%) |  |
 PH type 2 | 6 (10.2%) | 3 (5.1%) |  |
Subarachnoid hemorrhage | 6 (10.2%) | 0 | 0.027a |
Intraventricular hemorrhage | 8 (13.6%) | 1 (1.7%) | 0.032a |
Serious hemorrhagic complicationb | 9 (15.3%) | 3 (5.1%) | 0.068 |
Final infarct volume, ml (median, IQR) | 38.8 (14.3–92.7) | 18.5 (7.9–37.2) | 0.023 |
mRS 0–2 at 3 months | 19 (32.2%) | 31 (52.5%) | 0.025 |
Mortality | 12 (20.3%) | 4 (6.8%) | 0.031 |